Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs

Area of Science:

• Pharmacology
• Respiratory Medicine
• Drug Development

Background:

• Selective bronchodilator beta2-adrenoceptor agonists are key for managing respiratory diseases.
• Current pharmacodynamic approaches yield high beta2-adrenoceptor specificity but cause side effects like tremor and palpitations.
• Beta2-adrenoceptors in airways, skeletal muscle, and blood vessels are pharmacologically similar, complicating selectivity.

Purpose of the Study:

• To review the development of selective bronchodilator beta2-adrenoceptor agonists.
• To compare pharmacodynamic and pharmacokinetic strategies for achieving lung selectivity.
• To evaluate the potential of prodrugs for reducing side effects.

Main Methods:

• Review of pharmacodynamic approaches targeting beta2-adrenoceptor specificity.
• Analysis of pharmacokinetic approaches converting existing agonists into lung-selective prodrugs.
• Assessment of drug selectivity and side effect profiles.

Main Results:

• Pharmacodynamic approaches achieve high beta2-adrenoceptor specificity but retain side effects.
• Side effects are attributed to the indistinguishable nature of beta2-adrenoceptors in different tissues.
• The prodrug pharmacokinetic approach demonstrates potential for selective bronchodilation with reduced adverse effects.

Conclusions:

• Pharmacodynamic strategies for selective bronchodilators have limitations due to receptor similarity.
• The pharmacokinetic prodrug approach offers a promising avenue for developing safer, lung-selective bronchodilators.
• Further research into prodrug strategies could significantly improve treatment outcomes for respiratory conditions.